€15m · Seed · Healthtech · Paterna, Spain
Paterna-based molecular diagnostics company iPremom has raised €15m in Seed funding led by Amadeus Capital Partners and co-led by Asabys Partners, with APEX Ventures participating. According to Asabys, the capital will fund further clinical validation, the commercial rollout of iPremom's MaiRa platform and work towards regulatory approvals in the EU and US.
MaiRa is designed to estimate the risk of pregnancy complications from a maternal blood sample taken in the first trimester. The test analyses circulating cell-free RNA, including molecular signals associated with preeclampsia, and uses predictive software to generate a risk assessment for clinicians. iPremom's patient material is careful about the boundary: MaiRa is not a diagnosis, but a tool intended to support earlier monitoring and medical decisions.
Clinical evidence has to become a repeatable care pathway
The platform grew out of the PREMOM study, a prospective multicentre programme involving around 9,600 pregnancies across 14 hospitals and 26,000 collected samples, according to iPremom's study summary. A 2025 Nature Communications paper analysed a selected case-control cohort of 216 participants. Its first-trimester model predicted early-onset preeclampsia an average of 18 weeks before diagnosis, with an AUC of 0.88 in the study set and 0.87 in external validation.
Those results provide a scientific basis for the product, but the financing is aimed at the next layer of execution. The investor announcement says MaiRa is already available in Spain through iPremom's laboratory, while broader commercial launch and regulatory approvals remain work in progress. Moving from a research cohort to routine prenatal care requires consistent sample handling, laboratory turnaround, clinician interpretation and evidence that travels across patient populations and health systems.
The blood draw is simple; distribution is not
A test that starts with an ordinary maternal blood sample can fit an existing prenatal appointment more easily than a new imaging or invasive procedure. Yet its commercial model still depends on laboratories and clinicians incorporating the result into first-trimester workflows. iPremom says reports are returned within 21 days, making logistics and timing part of the product rather than a back-office detail.
The Seed round therefore backs both validation and distribution. More evidence can support regulatory review and clinician confidence; a repeatable laboratory workflow can turn that evidence into a service that reaches patients. The key milestone is not only whether MaiRa identifies molecular risk signals, but whether iPremom can deliver those signals early enough, consistently enough and with the clinical context needed to influence care.
